Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03450343 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT03450343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03450343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Lead sponsor
Medical University of South Carolina
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2019
Completion date
January 30, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell diffuse lymphoma